Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
Scope of the Report:
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
The worldwide market for Drugs for Vulvovaginal Candidiasis is expected to grow at a CAGR of roughly 2.1% over the next five years, will reach 870 million US$ in 2024, from 770 million US$ in 2019, according to a new WMR study.
This report focuses on the Drugs for Vulvovaginal Candidiasis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
J & J
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
Hospital & Clinic
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales, revenue and global market share of Drugs for Vulvovaginal Candidiasis in 2017 and 2018.
Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion, appendix and data source.